U.S. Hotel and Resort REITs Stock News

Clover Health Investments has delivered a very strong 215.9% return over the past three years, yet the broader valuation checks still suggest the stock screens as undervalued on several fronts. The share price pullback over the past month sits against solid multi year gains and a high value score that points to a market price that may not fully reflect the underlying fundamentals. Over three years, Clover Health Investments has returned 215.9%, which puts a spotlight on whether recent gains...

AvalonBay Communities and Equity Residential have agreed to merge as equals and have introduced Vivmark Residential as the new combined company name. The merger will create one of the largest multifamily residential real estate companies in the sector. The announcement is drawing attention because of its scale and the potential impact on competition and investor focus in residential REITs. AvalonBay Communities, ticker NYSE:AVB, is entering this merger with a recent share price of $185.61...

Cooling signals from the Fed’s preferred inflation gauges, including the Dallas Fed trimmed mean dropping to 1.4% in June, are giving growth investors a fresh data point to think about. Inflation is still above the Fed’s 2% target on traditional measures and some officials remain hawkish, so the rate path is not yet settled. That mix of softer alternative readings and firm policy talk can matter a lot for growth stocks with strong expansion plans. This article looks at 3 stocks from our...

Merck stock has more than doubled over the past five years, yet the latest valuation checks send a mixed message, with the Discounted Cash Flow (DCF) estimate pointing to meaningful upside while market based multiples look closer to in line. Merck has returned 101.7% over 5 years, which puts the current share price in a very different place to where long term holders started. Progress on products such as the once monthly HIV PrEP candidate alimatravir and expanded use of KEYTRUDA can support...

German American Bancorp, Inc. reported past second-quarter 2026 results showing net interest income of US$81.21 million and net income of US$38.17 million, alongside a regular quarterly dividend declaration of US$0.31 per share payable on August 20, 2026. An interesting insight for shareholders is that stronger earnings coincided with lower net charge-offs of US$673,000 compared with US$848,000 a year earlier, supporting the company’s dividend-paying capacity. We’ll now examine how German...

TransMedics Group stock has more than doubled over the past five years, yet the broader valuation checks still lean cheap, which puts fresh attention on whether the recent pullback has gone too far or not far enough. Over the past five years, TransMedics Group has returned about 150.4% which keeps the long term story attractive even after a weaker recent stretch. Future execution on transplant system adoption can support higher earnings power. However, any slowdown in procedure volumes or...

Deluxe has delivered a strong 75.2% return over the past year, yet the broader valuation checks still suggest the stock screens as cheap rather than stretched at the current US$25.87 share price. The 75.2% one year gain puts Deluxe among the stronger recent performers. This can raise the bar for what now counts as a reasonable entry price. The recently closed acquisition of Celero Commerce may support expectations for a larger payments platform, while the risk is that integration hurdles or...

CRISPR Therapeutics has delivered a steep share price decline of about 64.9% over the past 5 years, yet on broad valuation checks the stock now looks closer to fairly valued than like a clear bargain or clear bubble. The roughly 64.9% slide over 5 years highlights how much long term shareholders have given up in returns, which naturally raises the bar for any new investment case. Progress on CRISPR Therapeutics' allogeneic CAR-T programs, including the Phase 1 work on CTX112 aimed at off the...

InnovAge Holding (INNV) has filed a shelf registration for up to US$1.31 billion of common stock, covering 112,988,070 shares. This filing gives the company scope to raise equity capital when conditions appear suitable. See our latest analysis for InnovAge Holding. The shelf registration arrives after a strong period for InnovAge Holding, with the share price up 36.54% over 90 days and a year to date share price return of 118.88%. The 1 year total shareholder return of 262.94% points to...

In late July 2026, Western Alliance Bancorporation’s board declared a quarterly US$0.42 common dividend and a US$106.25 per share Series A preferred dividend alongside second-quarter results showing higher net interest income and net income than a year earlier. The combination of rising quarterly earnings, lower net loan charge-offs compared with the prior quarter, and continued share repurchases underpins a picture of active capital management and shareholder returns at the bank. We’ll now...

Stryker (SYK) has drawn fresh investor attention after reporting second quarter 2026 results, with sales of US$6.6b and net income of US$1.3b, alongside higher earnings per share from continuing operations. See our latest analysis for Stryker. The sharp 1 day share price decline of 6.42% to US$325.70 after Stryker’s earnings reflects investor focus on softer organic sales and ongoing supply disruptions, even though the 3 month share price return of 10.51% and 5 year total shareholder return...

Dutch Bros stock has delivered a strong 128.3% return over the past three years, yet the valuation checks currently lean expensive and suggest the recent share price near US$65.83 leaves less obvious room for error. Over the past three years, Dutch Bros has returned 128.3%, which puts extra focus on whether the current price still reflects a reasonable balance between growth expectations and risk. Expectations for continued store expansion and revenue growth can support a premium valuation...

Fresh conflict in the Middle East, rising energy prices and renewed inflation worries are shaking confidence in the 2026 stock market rally. For investors watching AI infrastructure enablers, that combination of higher costs and volatility can either pressure margins or create openings. This article looks at how the latest news links back to AI infrastructure related stocks, and why some could still look relatively well positioned while others may face tougher headwinds. The focus is on three...

Element Solutions Inc reported its second-quarter 2026 results, with sales rising to US$977.9 million from US$625.2 million and net income increasing to US$77.3 million from US$47.4 million, while a previously authorized buyback program saw no repurchases in the latest quarter but has cumulatively retired 63,734,799 shares for US$817.8 million since 2018. An interesting twist is that while quarterly revenue and earnings grew compared with a year earlier, net income for the first half of 2026...

Paylocity Holding stock has had a difficult run over the past five years, while current checks send mixed valuation signals, with the Discounted Cash Flow (DCF) intrinsic value pointing to a large gap to the current price and the market multiples implying the shares are not cheap. Paylocity Holding has declined 43.0% over five years, which raises the question of whether the current price reflects overly cautious expectations or ongoing concerns. New AI driven products such as Paylocity...

FirstCash Holdings (FCFS) has caught investor attention after reporting higher revenue and net income for the second quarter and first half of 2026, alongside completing a US$150 million share repurchase program. See our latest analysis for FirstCash Holdings. The recent share repurchase activity, leadership transition announcement and stronger earnings have come alongside a 30.1% year to date share price return for FirstCash Holdings. The 1 year total shareholder return of 57.2% and 5 year...

Universal Display stock has fallen a long way, with the share price down about 59.5% over the past five years, yet some valuation checks now flag it as potentially inexpensive relative to its fundamentals. After the company recently signalled that this year’s revenue is likely to come in at the lower end of its earlier range, investors are weighing that weaker outlook against a stock that already carries a long multi year decline. The roughly 59.5% decline over five years suggests many...

Global inflation questions, higher long term yields and energy price shocks are pushing investors to think harder about what really drives long run growth. One theme cutting across AI data centers, electric vehicles and power grids is copper supply. The Top Copper Stocks screener focuses on producers with stronger balance sheets and lower production costs, which can matter when prices move around. This article highlights three of the top stocks from that screener and explains how they fit...

Solventum (NYSE:SOLV) appointed Neil Zieselman as Senior Vice President, Controller and Chief Accounting Officer. Zieselman brings finance leadership experience from prior roles at Surgery Partners Inc. and Stryker Corporation. The appointment places him in a key role overseeing Solventum's accounting and financial reporting functions. Solventum operates in the healthcare sector, where accounting rigor and clear financial reporting are closely watched by investors and regulators. A new...

Equifax stock has fallen about 29% over the past five years, yet the latest Discounted Cash Flow (DCF) estimate suggests the intrinsic value could sit well above where the market is pricing the shares today, while earnings-based multiples look closer to fair. Over five years the share price is down about 29%, which means long-term holders have seen material capital pressure even before considering today’s valuation checks. Recent revenue growth, the planned acquisition in Mexico and expanded...

Cencora stock has delivered strong long term returns over the past five years, yet the current share price still screens as cheap relative to its intrinsic value estimate and traditional valuation multiples. With both the Discounted Cash Flow (DCF) model and the market based checks pointing in the same direction, investors are weighing how much of Cencora's story is already reflected in the price. Cencora has returned 171.7% over the past five years, which puts the recent valuation signals...

Amneal Pharmaceuticals stock has delivered a very strong 345.7% return over the past 3 years, yet its valuation checks lean more on the expensive side rather than flagging it as a clear bargain. Over the last 3 years Amneal Pharmaceuticals has returned 345.7%, which puts extra focus on whether the current share price already reflects much of the good news. Recent earnings strength and higher expectations for future revenue and profit can support the current valuation, but any disappointment...

Global markets are being pulled in different directions by inflation questions, shifting rate expectations and uneven growth across regions. In this kind of backdrop, many investors are looking past quarterly headlines and focusing on founders who are deeply invested in the long term. The Top Founder-Led Companies screener targets leaders with significant skin in the game and tight capital discipline. That combination can help align your interests with theirs, regardless of which sector is in...

In July 2026, Xerox Holdings Corporation reported second-quarter results showing revenue of US$1,922 million and net income of US$13 million, alongside a smaller six-month net loss and higher year-to-date revenue versus the prior year. The company also raised its full-year 2026 guidance to approximately US$7.60 billion in revenue and increased synergy targets from its Lexmark collaboration, highlighting progress on priorities to stabilize revenue, improve profitability, and reduce...